Literature DB >> 21327948

Inhibitory effect of drug-free hybrid liposomes on metastasis of human neuroblastoma.

Jyoji Yoshizawa1, Yuka Negishi, Yoko Matsumoto, Ryuichi Ueoka, Takao Ohki.   

Abstract

PURPOSE: Hybrid liposomes composed of vesicular and micellar molecules have been used as drug-delivery systems. It has become clear that hybrid liposomes alone have an inhibitory effect against the growth of various tumor cells. The present study was designed to determine whether a drug-free hybrid liposome composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylenealkyl ether (EO) [90 mol% DMPC/10% C(12)(EO)(21) (HL21), 90 mol% DMPC/10% C(12)(EO)(23) (HL23), or 90 mol% DMPC/10% C(12)(EO)(25) (HL25)], inhibit the liver metastasis of human neuroblastoma cells and thus increases survival.
METHODS: A human neuroblastoma cell, TNB9, and BALB/C-nu/nu athymic mice were used in this study. First, we determined the inhibitory effect of the hybrid liposomes on TNB9 cells in vitro. Next, to determine the inhibitory effect of the hybrid liposomes on metastasis of neuroblastoma cells to the liver, we made a murine hepatic metastasis model by implanting TNB9 cells (2 × 106) in the spleen of the mice and compared anatomic appearance, weights, and histological findings of the livers of treated mice and control mice 60 days after the beginning of a 7-day intraperitoneal injection of a hybrid liposome. We also compared survival rates using the Kaplan-Meier method.
RESULTS: In mice implanted with TNB9 neuroblastoma cells and treated with HL21 or HL25, no histological evidence of metastasis was found, the weight of the liver was normal, and survival was a mean of 88 and 87.9 days, respectively. In contrast, mice treated with HL23 and control mice had countless tumor cell masses histologically, their liver weight was increased, and their survival was 73.0 and 68.6 days, respectively.
CONCLUSIONS: Two kinds of hybrid liposomes, HL21 and HL25, inhibit metastasis of human neuroblastoma cells to the liver, and thus increase survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327948     DOI: 10.1007/s00383-010-2804-1

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  18 in total

1.  Highly specific inhibitory effect of three-component hybrid liposomes including sugar surfactants on the growth of glioma cells.

Authors:  Y Matsumoto; T Kato; H Suzuki; S Hirose; Y Naiki; M Hirashima; R Ueoka
Journal:  Bioorg Med Chem Lett       Date:  2000-12-04       Impact factor: 2.823

2.  [Specific inhibitory effects of hybrid liposomes on the growth of various tumor cells].

Authors:  Y Matsumoto; T Kato; S Iseki; H Suzuki; K Nakano; R Ueoka
Journal:  Yakugaku Zasshi       Date:  1999-04       Impact factor: 0.302

3.  Specific accumulation and growth inhibitory effects of hybrid liposomes to hepatoma cells in vitro.

Authors:  Koji Nakano; Yasunori Iwamoto; Wataru Takata; Yoko Matsumoto; Ryuichi Ueoka
Journal:  Bioorg Med Chem Lett       Date:  2002-11-18       Impact factor: 2.823

4.  Specific inhibitory effect of hybrid liposomes on growth of human lymphoma-human lymphocyte B hybridoma cells in vitro.

Authors:  Y Matsumoto; E Yamada; J Hirano; M Oshige; M Iio; M Iwahara; R Ueoka
Journal:  Biol Pharm Bull       Date:  1993-02       Impact factor: 2.233

5.  Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma.

Authors:  J Yoshizawa; R Mizuno; T Yoshida; A Hara; S Ashizuka; M Kanai; N Kuwashima; M Kurobe; Y Yamazaki
Journal:  J Surg Res       Date:  2000-09       Impact factor: 2.192

6.  Remarkably enhanced inhibitory effects of three-component hybrid liposomes including sugar surfactants on the growth of lung carcinoma cells.

Authors:  Ryuichi Ueoka; Yoko Matsumoto; Shigeru Hirose; Koichi Goto; Masahiro Goto; Shintaro Furusaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  2002-04       Impact factor: 1.645

7.  Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration.

Authors:  A Rahman; N More; P S Schein
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

8.  Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats.

Authors:  T M Allen; J M Everest
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

9.  Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma.

Authors:  Minoru Kuroiwa; Toshiyuki Takeuchi; Jung Hee Lee; Jyoji Yoshizawa; Junko Hirato; Setsuko Kaneko; Seung Hoon Choi; Norio Suzuki; Hitoshi Ikeda; Yoshiaki Tsuchida
Journal:  J Pediatr Surg       Date:  2003-10       Impact factor: 2.545

10.  Remarkably high inhibitory effects of docosahexaenoic acid incorporated into hybrid liposomes on the growth of tumor cells along with apoptosis.

Authors:  Yoshihiro Tanaka; Koichi Goto; Yoko Matsumoto; Ryuichi Ueoka
Journal:  Int J Pharm       Date:  2008-04-08       Impact factor: 5.875

View more
  1 in total

1.  Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells.

Authors:  Hideki Kitajima; Yuji Komizu; Hideaki Ichihara; Koichi Goto; Ryuichi Ueoka
Journal:  Cancer Med       Date:  2013-03-22       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.